Skip to main content

Dr. Robert Redfield, Co-Founder of the Institute of Human Virology at the University of Maryland School of Medicine, to Become CDC Director

March 21, 2018 | Nora Samaranayake

Robert R. Redfield, MD

Renowned Clinical AIDS Researcher, Public Health Expert and Chief of Infectious Diseases Has Decades of Experience

Wednesday, March 21, 2018: The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) congratulates its co-founder and associate director, Robert R. Redfield, MD, on his appointment to be the next director of the U.S. Centers for Disease Control and Prevention (CDC).

“Dr. Robert Redfield, a close colleague for more than 40 years, is an excellent choice to be head of the CDC,” said Robert C. Gallo, MD, the Homer & Martha Gudelsky Distinguished Professor in Medicine, co-founder and director of the IHV and co-founder and scientific director of the Global Virus Network (GVN).  “While it will be a big loss for the Institute, we are at a time in our nation’s history when Dr. Redfield’s skills will best be utilized as head of the CDC. He has been an outstanding leader as head of the Institute’s Clinical Care and Research Division, and a major force in establishing our clinical public health programs in Baltimore to confront the HIV and hepatitis C epidemics in our City and State. With his leadership, Dr. Redfield has also contributed greatly to the Institute’s global health programs.”

Dr. Redfield is a renowned infectious disease expert, beginning his career in the late 1970’s at the Walter Reed Army Medical Center. He then co-founded the Institute of Human Virology in 1996. During his military service, Dr. Redfield made several important scientific contributions to the early understanding of HIV/AIDS.  Under his leadership, the Institute’s patient base has grown from just 200 patients to approximately 6,000 in Baltimore and Washington, D.C., and more than 1.3 million in African and Caribbean nations. At the Institute, Dr. Redfield’s research focused on novel strategies to innovatively target host cell pathways to treat and prevent HIV infection and other viral diseases. He is also the Robert C. Gallo, MD Endowed Professor in Translational Medicine, Chief of Infectious Diseases and Vice Chair of Medicine for Clinical Affairs in the UMSOM Department of Medicine.

“Dr. Redfield was one of my early collaborators in co-discovering HIV as the cause of AIDS and demonstrating heterosexual transmission of AIDS,” said Dr. Gallo. “He is a dedicated and compassionate physician who truly cares about his patients and is deeply committed to ensuring patients receive the highest quality of care possible. Dr. Redfield has served his country well, and consistently demonstrates strong public health instincts that are grounded in science and clinical medicine. In my view, despite the loss to the Institute, I believe this makes him the ideal candidate to direct the CDC.”

“Dr. Redfield is eminently qualified for this critical position,” said E. Albert Reece, MD, PhD, MBA, Executive Vice President for Medical Affairs, UM Baltimore, and the John Z. Akiko Bowers Distinguished Professor and Dean, University of Maryland School of Medicine. "He has made a lifelong commitment to advancing biomedical research and human health through discovery-based medicine. As co-founder of the University of Maryland School of Medicine’s Institute of Human Virology with Dr. Robert Gallo and Dr. William Blattner, he has been one of the most accomplished scientists and public health advocates in the nation in increasing our understanding of the prevention and treatment of infectious disease. His significant contributions have led to the treatment of more than a million HIV patients by the Institute in the U.S. and around the world.  We wish him great success in this vital role as the nation’s chief protector against the growing threat of infectious disease.”

"Dr. Redfield's longstanding commitment to clinical research and treatment of people with chronic viral infections speaks for itself," said Jay A. Perman, MD, president of the University of Maryland, Baltimore. "Through his vision and leadership, the university's expertise has been leveraged to treat and care for hundreds of thousands of HIV/AIDS patients throughout Africa and in the Caribbean, and here in our region. I have no doubt that Dr. Redfield will serve this nation extraordinarily well as the leader of its health security agency, the Centers for Disease Control."

“Dr. Redfield is so deserving of this wonderful honor and opportunity,” said Stephen N. Davis, MBBS, the Dr. Theodore E. Woodward Professor and Chair of Medicine at UMSOM. “Dr. Redfield has made landmark contributions, consistently, to the Department of Medicine at the University of Maryland School of Medicine. His fund of medical knowledge is incredible. He is a compassionate, thoughtful and astute physician. His innovative research has led him to become a renowned national and international expert on diagnosing, prevention and management of infectious diseases at both a population and individual level. His exceptional skill as a clinical researcher has allowed him and his teams to make transformative medical breakthroughs both in the US and worldwide. Dr. Redfield is also an immensely talented teacher and skillful administrator. We will miss him tremendously but are so delighted that he will be able to focus his unique abilities on improving the health of this great nation, and indeed the world.”

“Dr. Redfield’s appointment to Director of CDC is a brilliant recognition of a great public health advocate, an excellent researcher, and one that has a life of dedication to-public service,” said Terry Lierman, Chairman of IHV’s Board of Advisors. “This appointment is refreshingly not about politics, but about quality, competence and compassion. Dr. Redfield encompasses all of those qualities and more.”

About the Institute of Human Virology

Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders - most notably, HIV the virus that causes AIDS. For more information, and follow us on Twitter @IHVmaryland.

About the University of Maryland School of Medicine

Commemorating its 210th Anniversary, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 43 academic departments, centers, institutes, and programs; and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished recipient of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically-based care for more than 1.2 million patients each year. The School has over 2,500 students, residents, and fellows, and nearly $450 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding. As one of the seven professional schools that make up the University of Maryland Baltimore campus, the School of Medicine has a total workforce of nearly 7,000 individuals. The combined School and Medical System (“University of Maryland Medicine”) has an annual budget of nearly $6 billion and an economic impact in excess of $15 billion on the state and local community. The School of Medicine faculty, which ranks as the 8th-highest public medical school in research productivity, is an innovator in translational medicine, with 600 active patents and 24 start-up companies. The School works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit


Institute of Human Virology
Jennifer Gonzales
Public Relations & Communications Manager

Related stories

    Tuesday, March 28, 2023

    Two-Time Lasker Awardee and Internationally Acclaimed Virologist, Robert C. Gallo, MD, To Step Down as Director of UM School of Medicine’s Institute of Human Virology (IHV)

    Robert C. Gallo, MD, one of the world’s leading virologists and cancer researchers, announced he has stepped down from his position as Director of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), effective March 24.

    Wednesday, November 09, 2022

    Lishan Su, PhD, Invested as the UMSOM Charles Gordon Smith Endowed Professor for HIV Research

    With his 92-year-old mother watching via live stream from the city of Qingdao, China, and an in-person audience of friends and colleagues gathered in Westminster Hall, Lishan Su, PhD, an internationally prominent virologist and immunologist at the University of Maryland School of Medicine’s (UMSOM) Institute of Human Virology (IHV), was invested as the Charles Gordon Smith Endowed Professor for HIV Research. Dr. Su is a Professor in the Departments of Pharmacology and Microbiology & Immunology at UMSOM’s IHV, who also serves as the Director of the Division of Virology, Pathogenesis, and Cancer at the Institute.

    Monday, October 31, 2022

    NCI Grants Awarded to IHV to Prevent Cancer and Improve Screening in Sub-Saharan Africa

    Institute of Human Virology (IHV) researchers at the University of Maryland School of Medicine (UMSOM) have received two five-year awards from the National Institutes of Health’s National Cancer Institute (NCI) for a total of $7.5 million. One award aims to reduce the incidence of lung cancer and other cancers associated with using tobacco in Botswana. The other is focusing on improving screening and treatment of anal precancer in Nigeria. Both grants will make use of existing HIV treatment and prevention infrastructure in low- and middle-income countries to reach people living with HIV who are most at risk for these particular types of cancers.

    Tuesday, February 15, 2022

    Multi-Country African Research Reports High Rates of COVID-19-Related Deaths Among Hospitalized Children and Adolescents

    African children and adolescents hospitalized with COVID-19 experience much higher mortality rates than Europeans or North Americans of the same age, according to a recently published study conducted by researchers from the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and the Institute of Human Virology Nigeria (IHVN). Both organizations are members of the Global Virus Network (GVN).

    Wednesday, December 01, 2021

    $6.5M Grant Awarded to Develop Treatment for Alcoholic Liver Disease-Associated Kidney Dysfunction

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) and MitoPower LLC (“MitoPower”) were awarded an SBIR (Small Business Innovation Research) grant of up to $6.5 million over five years from the National Institute on Alcohol Abuse and Alcoholism. The funds will support the development of MitoPower’s lead compound, MP-04, for the treatment of kidney dysfunction due to alcoholic liver disease, a condition known as alcoholic liver disease-associated hepatorenal syndrome (HRS). The IHV, a Center of Excellence member of the Global Virus Network (GVN), will conduct first-in-human single and multiple ascending dose studies to test the safety of the compound, followed by a Phase 1b study in patients.

    Tuesday, December 15, 2020

    UMSOM Institute of Human Virology’s Shyam Kottilil, MBBS, PhD Receives Top Award from National Physician’s Group

    Shyam Kottilil, MBBS, PhD, professor of medicine at the University of Maryland School of Medicine (UMSOM), and Director of UMSOM’s Institute of Human Virology (IHV) Division of Clinical Care and Research, has been awarded Mastership in the American College of Physicians (ACP), the national organization of internists. Dr. Kottilil is also Chief of the Division of Infectious Diseases in the UMSOM Department of Medicine and is a scientific advisory member of the Global Virus Network (GVN).

    Thursday, March 21, 2019

    IHV Experts Researching Experimental Drug to Curb Opioid Cravings

    Researchers at the University of Maryland School of Medicine (UMSOM) Institute of Human Virology (IHV) are collaborating with scientists at the National Institutes of Health to test an experimental drug to curb opioid cravings.

    Wednesday, March 06, 2019

    UMSOM Researcher Elected as Fellow to American Academy of Microbiology

    Richard Y. Zhao, Ph.D., Professor of Pathology and Associate Member of the Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM), has been elected as a Fellow to the American Academy of Microbiology (AAM). AAM is an honorific leadership group within the American Society for Microbiology (ASM).

    Tuesday, December 04, 2018

    Institute of Human Virology Researchers Discover That a Bacterial Protein Promotes Cancer

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine (UMSOM) announced today the discovery that DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell’s ability to respond to and repair DNA damage, a known origin of cancer.

    Wednesday, September 19, 2018

    Institute of Human Virology (IHV) Awarded $12M to Combat Opioid Epidemic Through Clinical Research Trials

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine will lead a $12 million dollar project to improve the morbidity and mortality of people with opioid use disorder (OUD). Utilizing a novel compound, IHV researches will implement a series of investigations, entitled SEARCH, to evaluate the underlying mechanisms of craving reduction as a strategy to prevent opioid misuse, dependence, and relapse. The grant is awarded through the National Institutes of Health’s (NIH) Helping to End Addiction Long-term (HEAL) Initiative, made possible through groundbreaking funding from the U.S. Congress.

    Tuesday, March 20, 2018

    UMSOM Cancer Expert at Institute of Human Virology Named Fellow of American Society of Clinical Oncology

    Clement A. Adebamowo, BM, ChB, ScD, FWACS, FACS, Associate Director of Population Science at the Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine (UMSOM), and Professor of Epidemiology and Public Health, Institute of Human Virology, has been named a 2018 Fellow of the American Society of Clinical Oncology (ASCO).

    Tuesday, November 22, 2016

    IHV Awarded $138M to combat HIV/AIDS in Africa & Launches Center for International Health, Education, & Biosecurity

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine announced today more than $138 million in multiple five-year grants awarded by the Centers for Disease Control and Prevention to combat HIV/AIDS in Kenya, Tanzania, Zambia, and Nigeria. The Institute concurrently announced the formation of the IHV Center for International Health, Education, & Biosecurity (CIHEB), and its newly appointed director, Deus Bazira Mubangizi, DrPH, MBA, MPH, Assistant Professor of Medicine, Director, Center for Health, Education, & Biosecurity, Institute of Human Virology, University of Maryland School of Medicine.

    Wednesday, April 13, 2016

    IHV Releases Data Supporting Community-Based Treatment Providers in Fight Against Hepatitis C

    The Institute of Human Virology (IHV) at the University of Maryland School of Medicine released data today at The International Liver Congress 2016 in Barcelona, Spain demonstrating that treatment for hepatitis C virus (HCV) can be provided safely and effectively within a community-based and non-specialist setting.